D80-D89

Document the specific type of immune disorder and its primary or secondary nature. Clearly state the underlying cause if known (e.g., genetic defect, medication-induced). Detail all manifestations and affected organ systems.

Example: PATIENT: 45-year-old male with confirmed Common Variable Immunodeficiency (CVID), congenital/primary type, documented by persistently low IgG, IgA, and IgM levels, and impaired specific antibody responses. This chronic condition leads to recurrent sinopulmonary infections, including the current episode of left lower lobe pneumonia (lobar pattern confirmed by CXR) requiring hospitalization. Patient also has a history of CVID-associated chronic diarrhea and autoimmune thrombocytopenia. Regular IVIG infusions (last dose 3 weeks prior) are vital for management. CURRENT PLAN: Continue IVIG therapy as scheduled, admit for IV antibiotics for severe pneumonia, monitor platelet count for thrombocytopenia exacerbation. Billing Focus: 'D83.0 Common variable immunodeficiency with predominant abnormalities of B-cell numbers or function' captures the specific primary immune defect. 'J18.1 Lobar pneumonia, unspecified organism' for the acute infectious exacerbation. 'K52.9 Noninfectious gastroenteritis and colitis, unspecified' for chronic GI manifestations. 'D69.3 Immune thrombocytopenic purpura' for autoimmune complication. Risk Adjustment: The documentation explicitly links the recurrent, severe infections and autoimmune complications to the chronic, complex CVID (HCC 150 for CVID, HCC 84 for Autoimmune Hemolytic Anemia/Thrombocytopenia), reflecting the high burden of disease and need for ongoing, intensive management. Severity of illness is highlighted by hospitalization for pneumonia.

Billing Focus: Specificity of the immune disorder (e.g., 'D83.0' vs. 'D83.9 Unspecified common variable immunodeficiency'), laterality/site of infections, primary/secondary nature, and explicit linkage of complications (e.g., pneumonia, autoimmune conditions) to the immune deficiency.

Quantify the severity of immune compromise and frequency/severity of complications. Describe the impact on daily living and the need for ongoing treatment, such as immunoglobulin replacement or prophylactic medications.

Example: PATIENT: 7-year-old female with X-linked Agammaglobulinemia (XLA), chronic, presenting with a 3-day history of fever, otalgia, and purulent discharge from the right ear, consistent with acute otitis media (AOM) due to her underlying immunodeficiency. This is her third AOM episode in 6 months, despite weekly subcutaneous immunoglobulin (SCIG) infusions. Patient experiences significant school absenteeism due to recurrent infections, impacting her academic progress and social development. Current infection is managed with a 10-day course of high-dose amoxicillin. Her baseline IgG trough level (pre-SCIG) was 450 mg/dL, indicating stable but still low levels requiring ongoing replacement therapy. Billing Focus: 'D80.0 Hereditary hypogammaglobulinemia' is precise for XLA. 'H66.001 Acute suppurative otitis media, right ear, without spontaneous rupture of ear drum' for the acute infection. The 'recurrent' nature of infections, though not explicitly coded in ICD-10 for XLA, is captured by documenting multiple episodes. Risk Adjustment: Documenting the chronic nature of XLA (HCC 150) and the ongoing need for SCIG therapy (reflected in medication list) supports the risk adjustment model. The frequency of infections and impact on school attendance highlight the severity and functional impairment, contributing to a higher risk score. This indicates complexity and continued healthcare resource utilization.

Billing Focus: Documenting specific type of hereditary hypogammaglobulinemia (D80.0), laterality of acute infections (right ear), and the chronicity/recurrent nature of complications.

Clearly differentiate between primary (congenital/hereditary) and secondary (acquired) immune deficiencies. For secondary deficiencies, identify the causative agent or underlying disease (e.g., medication, HIV, malignancy).

Example: PATIENT: 68-year-old male with Multiple Myeloma (C90.00), currently undergoing chemotherapy with daratumumab, lenalidomide, and dexamethasone. Presents with fatigue and persistent productive cough for 2 weeks, now with fevers to 101.5°F. Lab results show severe neutropenia (ANC 0.8 K/uL) secondary to chemotherapy-induced immunosuppression. Chest CT reveals bilateral patchy infiltrates, highly suspicious for bacterial pneumonia. This is a severe, acquired immune deficiency directly attributable to active cancer treatment. The patient's functional status has declined significantly, requiring assistance with ADLs. Billing Focus: 'D89.81 Other specified disorders involving the immune mechanism, not elsewhere classified' could be used for chemotherapy-induced neutropenia. More specifically, 'D70.1 Agranulocytosis secondary to antineoplastic chemotherapy' is highly appropriate, along with 'J18.9 Pneumonia, unspecified organism' and 'C90.00 Multiple myeloma, not having achieved remission'. Linking the neutropenia to the chemotherapy regimen is crucial. Risk Adjustment: Documentation of the primary malignancy (Multiple Myeloma, HCC 124) and the severe, acquired immunosuppression due to chemotherapy (which often leads to HCCs for conditions like neutropenic fever or specific infections) accurately reflects disease burden. The active treatment and associated complications like severe neutropenia contribute to a higher risk score, indicating significant healthcare resource utilization and patient complexity.

Billing Focus: Clearly stating 'secondary to chemotherapy-induced immunosuppression' and using specific codes for the induced condition (e.g., 'D70.1' for neutropenia), alongside the primary malignancy and acute infection. This demonstrates causality.